期刊
CURRENT OPINION IN IMMUNOLOGY
卷 40, 期 -, 页码 96-102出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.03.006
关键词
-
类别
资金
- ETH Zurich
- Swiss National Science Foundation
- Bovena Foundation
- Maiores Foundation
- ERC
- National Institutes of Health (USA) [CA032685, CA87025, CA166105, CA14520, CA197078, GM067386]
- Midwest Athletes for Childhood Cancer Fund
- Crawdaddy Foundation
- Evan Dunbar Foundation
- Hyundai Hope on Wheels Foundation
- University of Wisconsin-Madison Institute for Clinical and Translational Research Grant [1TL1RR025013-01]
- Stand Up To Cancer - St. Baldrick's Pediatric Dream Team Translational Research Grant [SU2C-AACR-DT1113]
Immunocytokines are antibody-cytokine fusion proteins, with the potential to preferentially localize on tumor lesions and to activate anticancer immunity at the site of disease. Various tumor targets (e.g., cell membrane antigens and extracellular matrix components) and antibody formats (e.g., intact IgG and antibody fragments) have been considered for immunocytokine development and some products have advanced to clinical trials. In this review, we present relevant concepts and strategies for the design and use of anticancer immunocytokine products. In addition, we discuss emerging strategies for the pharmaceutical development and clinical application of this promising class of biopharmaceuticals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据